Abstract

BackgroundA new more highly sensitive rapid diagnostic test (HS-RDT) for Plasmodium falciparum malaria (Alere™/Abbott Malaria Ag P.f RDT [05FK140], now called NxTek™ Eliminate Malaria Ag Pf) was launched in 2017. The test has already been used in many research studies in a wide range of geographies and use cases.MethodsIn this study, we collate all published and available unpublished studies that use the HS-RDT and assess its performance in (i) prevalence surveys, (ii) clinical diagnosis, (iii) screening pregnant women, and (iv) active case detection. Two individual-level data sets from asymptomatic populations are used to fit logistic regression models to estimate the probability of HS-RDT positivity based on histidine-rich protein 2 (HRP2) concentration and parasite density. The performance of the HS-RDT in prevalence surveys is estimated by calculating the sensitivity and positive proportion in comparison to polymerase chain reaction (PCR) and conventional malaria RDTs.ResultsWe find that across 18 studies, in prevalence surveys, the mean sensitivity of the HS-RDT is estimated to be 56.1% (95% confidence interval [CI] 46.9–65.4%) compared to 44.3% (95% CI 32.6–56.0%) for a conventional RDT (co-RDT) when using nucleic acid amplification techniques as the reference standard. In studies where prevalence was estimated using both the HS-RDT and a co-RDT, we found that prevalence was on average 46% higher using a HS-RDT compared to a co-RDT. For use in clinical diagnosis and screening pregnant women, the HS-RDT was not significantly more sensitive than a co-RDT.ConclusionsOverall, the evidence presented here suggests that the HS-RDT is more sensitive in asymptomatic populations and could provide a marginal improvement in clinical diagnosis and screening pregnant women. Although the HS-RDT has limited temperature stability and shelf-life claims compared to co-RDTs, there is no evidence to suggest, given this test has the same cost as current RDTs, it would have any negative impacts in terms of malaria misdiagnosis if it were widely used in all four population groups explored here.

Highlights

  • A new more highly sensitive rapid diagnostic test (HS-Rapid diagnostic test (RDT)) for Plasmodium falciparum malaria (AlereTM/ Abbott Malaria Ag P.f Rapid diagnostic tests (RDTs) [05FK140], called NxTekTM Eliminate Malaria Ag Pf) was launched in 2017

  • Sensitivity of the HS‐RDT against histidine-rich protein 2 (HRP2) concentration The performance of the highly sensitive rapid diagnostic test (HS-RDT) on clinical samples based on HRP2 concentration was assessed by calculating the sensitivity amongst samples with different levels of HRP2

  • In samples with HRP2 concentrations > 1000 pg/ml, the HS-RDT had a mean sensitivity of 99.2% across the high- and low-transmission settings (Fig. 2A and B, respectively) and conventional RDTs (co-RDTs) had a sensitivity of > 89.0% in these same samples

Read more

Summary

Introduction

A new more highly sensitive rapid diagnostic test (HS-RDT) for Plasmodium falciparum malaria (AlereTM/ Abbott Malaria Ag P.f RDT [05FK140], called NxTekTM Eliminate Malaria Ag Pf) was launched in 2017. Rapid diagnostic tests (RDTs) and microscopy are the cornerstone of confirmation of clinical malaria diagnosis in most endemic countries and are widely used for prevalence surveys They have more limited use in Recently, a Plasmodium falciparum histidine-rich protein 2 (HRP2)–based RDT (AlereTM/Abbott Malaria Ag P.f. Slater et al BMC Infectious Diseases (2022) 22:121. An unprecedented wide range of studies has been conducted using the HS-RDT in a variety of transmission settings and use cases to investigate the practical benefits of its lower limit of detection (LOD). First and foremost, this test was intended to identify asymptomatic infections in mass screening and active case detection interventions, in low-transmission settings. To assess the utility of the HS-RDT, we need to better understand the how it performs in comparison to co-RDTs or more sensitive nucleic acid amplification–based tests (NAATs) (e.g., polymerase chain reaction [PCR]) and in different transmission settings

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call